We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Acadia Pharmaceuticals’ Nuplazid (pimavanserin) failed to meet its primary endpoint in two phase 3 clinical trials evaluating it for major depressive disorder. Read More
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
Preliminary data from a German phase 1/2 trial showed that Pfizer’s and BioNTech’s mRNA-based coronavirus vaccine candidate is safe and generated immune responses in participants, the companies announced Monday. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
Johnson & Johnson has announced that it will begin evaluating its experimental COVID-19 vaccine in its first clinical trial next week, beginning in Belgium on July 22 and the U.S. the following week. Read More